$599
Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics

NewAmsterdam, Insulet, and Biocon Q3 ’26 Earnings; G&L Maintenance data; Pfizer Ph3 Berobenatide Knee OA Study

A series of cardiometabolic-related news items has been observed from NewAmsterdam Pharma, Insulet, Gan & Lee, Pfizer, and Biocon. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here
OR
Return to Home